Ligand controling interaction between gags with their effector molecules and use thereof
US11357816B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 17, 2019 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Jun 17, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4725
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.